Published ahead of print on September 11, 2003, doi:10.1164/rccm.200306-731OC
Am. J. Respir. Crit. Care Med., Volume 168, Number 12, December 2003, 1471-1475
A more recent version of this article appeared on December 15, 2003
Submitted on June 4, 2003
Accepted on August 22, 2003
Inflammatory and Microbiologic Markers in Induced Sputum following IV Antibiotics in Cystic Fibrosis
Claudia L Ordonez1*, Noreen R Henig2, Nicole Mayer-Hamblett3, Frank J Accurso4, Jane L Burns3, James F Chmiel5, Cori L Daines6, Ronald L Gibson3, Sharon McNamara3, George Z Retsch-Bogart7, Pamela L Zeitlin8, and Moira L Aitken9
1 Medicine, Harvard Medical School, Children's Hospital, Boston, MA, USA,
2 Medicine, Stanford University School of Medicine, Stanford, CA, USA,
3 Pediatrics, University of Washington, Seattle, WA, USA,
4 Pediatrics, University of Colorado School of Medicine, Denver, CO, USA,
5 Pediatrics, Case Western Reserve University School of Medicine, Cleveland, OH, USA,
6 Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA,
7 Pediatrics, University of North Carolina, Chapel Hill, NC, USA,
8 Pediatrics, The Johns Hopkins University School of Medicine, Baltimore, MD, USA,
9 Medicine, University of Washington, Seattle, WA, USA
* To whom correspondence should be addressed. E-mail: claudia.ordonez{at}tch.harvard.edu.
Induced sputum has been used to study airway inflammation. We sought to determine whether markers of infection and inflammation in induced sputum were a useful and safe outcome measure in cystic fibrosis. We hypothesized that bacterial density and inflammatory content of induced sputum would decrease after antibiotic therapy. Induced sputum was assayed for bacterial density, cell count and differential and inflammatory markers before and after intravenous antibiotics. Fifty-five of 72 subjects enrolled (mean age ± standard deviation 18.2 ± 7.9 years) completed the study. FEV1 increased by an average 0.3 ± 0.3 L (10.4 ± 8.7% predicted FEV1), p<0.0001; density of P. aeruginosa and S. aureus decreased by 2.4 ± 3.1 log10 CFU/g (p<0.0005) and 4.0 ± 2.3 log10 CFU/mL (p<0.0001), respectively; neutrophil count decreased by 0.4 ± 0.6 log10 cells/mL (p<0.0001), interleukin-8 concentration by 0.5 ± 1.3 log10 pg/mL (p<0.05), and neutrophil elastase by 0.4 ± 0.7 log10 µg/mL (p<0.005). Seven of 127 (6%) sputum induction procedures had a decrease in FEV1 20%. We conclude that markers in induced sputum may be useful non-invasive outcome measures to assess response to therapies in cystic fibrosis studies.
Key words: cystic fibrosis, induced sputum, inflammatory markers, bacterial density
This article has been cited by other articles:

|
 |

|
 |
 
C. R. Esther Jr., G. Boysen, B. M. Olsen, L. B. Collins, A. J. Ghio, J. W. Swenberg, and R. C. Boucher
Mass spectrometric analysis of biomarkers and dilution markers in exhaled breath condensate reveals elevated purines in asthma and cystic fibrosis
Am J Physiol Lung Cell Mol Physiol,
June 1, 2009;
296(6):
L987 - L993.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Coote, H. C. Atherton-Watson, R. Sugar, A. Young, A. MacKenzie-Beevor, M. Gosling, G. Bhalay, G. Bloomfield, A. Dunstan, R. J. Bridges, et al.
Camostat Attenuates Airway Epithelial Sodium Channel Function in Vivo through the Inhibition of a Channel-Activating Protease
J. Pharmacol. Exp. Ther.,
May 1, 2009;
329(2):
764 - 774.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. T. Saavedra, G. J. Hughes, L. A. Sanders, M. Carr, D. M. Rodman, C. D. Coldren, M. W. Geraci, S. D. Sagel, F. J. Accurso, J. West, et al.
Circulating RNA Transcripts Identify Therapeutic Response in Cystic Fibrosis Lung Disease
Am. J. Respir. Crit. Care Med.,
November 1, 2008;
178(9):
929 - 938.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. M. Rowe, P. L. Jackson, G. Liu, M. Hardison, A. Livraghi, G. M. Solomon, D. B. McQuaid, B. D. Noerager, A. Gaggar, J. P. Clancy, et al.
Potential Role of High-Mobility Group Box 1 in Cystic Fibrosis Airway Disease
Am. J. Respir. Crit. Care Med.,
October 15, 2008;
178(8):
822 - 831.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Griese, M. Kappler, A. Gaggar, and D. Hartl
Inhibition of airway proteases in cystic fibrosis lung disease
Eur. Respir. J.,
September 1, 2008;
32(3):
783 - 795.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. R. Esther Jr, N. E. Alexis, M. L. Clas, E. R. Lazarowski, S. H. Donaldson, C. M. Pedrosa Ribeiro, C. G. Moore, S. D. Davis, and R. C. Boucher
Extracellular purines are biomarkers of neutrophilic airway inflammation
Eur. Respir. J.,
May 1, 2008;
31(5):
949 - 956.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Gaggar, P. L. Jackson, B. D. Noerager, P. J. O'Reilly, D. B. McQuaid, S. M. Rowe, J. P. Clancy, and J. E. Blalock
A Novel Proteolytic Cascade Generates an Extracellular Matrix-Derived Chemoattractant in Chronic Neutrophilic Inflammation
J. Immunol.,
April 15, 2008;
180(8):
5662 - 5669.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Mussaffi, E. M. Fireman, M. Mei-Zahav, D. Prais, and H. Blau
Induced Sputum in the Very Young: A New Key to Infection and Inflammation
Chest,
January 1, 2008;
133(1):
176 - 182.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Dovey, M. L. Aitken, J. Emerson, S. McNamara, D. A. Waltz, and R. L. Gibson
Oral Corticosteroid Therapy in Cystic Fibrosis Patients Hospitalized for Pulmonary Exacerbation: A Pilot Study
Chest,
October 1, 2007;
132(4):
1212 - 1218.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. D. Sagel, J. F. Chmiel, and M. W. Konstan
Sputum Biomarkers of Inflammation in Cystic Fibrosis Lung Disease
Proceedings of the ATS,
August 1, 2007;
4(4):
406 - 417.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Gaggar, Y. Li, N. Weathington, M. Winkler, M. Kong, P. Jackson, J. E. Blalock, and J. P. Clancy
Matrix metalloprotease-9 dysregulation in lower airway secretions of cystic fibrosis patients
Am J Physiol Lung Cell Mol Physiol,
July 1, 2007;
293(1):
L96 - L104.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Mayer-Hamblett, M. L. Aitken, F. J. Accurso, R. A. Kronmal, M. W. Konstan, J. L. Burns, S. D. Sagel, and B. W. Ramsey
Association between Pulmonary Function and Sputum Biomarkers in Cystic Fibrosis
Am. J. Respir. Crit. Care Med.,
April 15, 2007;
175(8):
822 - 828.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. H Goss and J. L Burns
Exacerbations in cystic fibrosis {middle dot} 1: Epidemiology and pathogenesis
Thorax,
April 1, 2007;
62(4):
360 - 367.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S Rao and J Grigg
New insights into pulmonary inflammation in cystic fibrosis.
Arch. Dis. Child.,
September 1, 2006;
91(9):
786 - 788.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Grasemann, R. Schwiertz, S. Matthiesen, K. Racke, and F. Ratjen
Increased Arginase Activity in Cystic Fibrosis Airways
Am. J. Respir. Crit. Care Med.,
December 15, 2005;
172(12):
1523 - 1528.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. J. Sloane, R. A. Lindner, S. S. Prasad, L. T. Sebastian, S. K. Pedersen, M. Robinson, P. T. Bye, D. W. Nielson, and J. L. Harry
Proteomic Analysis of Sputum from Adults and Children with Cystic Fibrosis and from Control Subjects
Am. J. Respir. Crit. Care Med.,
December 1, 2005;
172(11):
1416 - 1426.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. M. Moskowitz, J. M. Foster, J. C. Emerson, R. L. Gibson, and J. L. Burns
Use of Pseudomonas biofilm susceptibilities to assign simulated antibiotic regimens for cystic fibrosis airway infection
J. Antimicrob. Chemother.,
November 1, 2005;
56(5):
879 - 886.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A. Kamboures, D. R. Blake, D. M. Cooper, R. L. Newcomb, M. Barker, J. K. Larson, S. Meinardi, E. Nussbaum, and F. S. Rowland
Breath sulfides and pulmonary function in cystic fibrosis
PNAS,
November 1, 2005;
102(44):
15762 - 15767.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Xiao, Y.-P. Hsu, A. Ishizaka, T. Kirikae, and R. B. Moss
Sputum Cathelicidin, Urokinase Plasminogen Activation System Components, and Cytokines Discriminate Cystic Fibrosis, COPD, and Asthma Inflammation
Chest,
October 1, 2005;
128(4):
2316 - 2326.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Wagner, G. Soong, S. Sokol, L. Saiman, and A. Prince
Effects of Azithromycin on Clinical Isolates of Pseudomonas aeruginosa From Cystic Fibrosis Patients
Chest,
August 1, 2005;
128(2):
912 - 919.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. J. Tobin
Pediatrics, Surfactant, and Cystic Fibrosis in AJRCCM 2003
Am. J. Respir. Crit. Care Med.,
January 15, 2004;
169(2):
277 - 287.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. S. Armstrong
In Celebration of Expectoration: Induced Sputum Indices as Outcome Measures in Cystic Fibrosis
Am. J. Respir. Crit. Care Med.,
December 15, 2003;
168(12):
1412 - 1413.
[Full Text]
[PDF]
|
 |
|
Copyright © 2003 American Thoracic Society
|
|
|